Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.
Psychedelic-Assisted Therapy Training
Psychedelic therapy represents a paradigm shift in mental health treatment, combining the unique pharmacological effects of psychoactive substances with expert psychological support. Our comprehensive training program equips mental health professionals with the knowledge and skills needed to navigate this emerging field effectively.
Psychedelic
Therapy
Education for the Psychedelic Renaissance
Our continuing education courses are designed to meet the growing demand for specialized training in psychedelic medicine. We provide in-depth guidance and support for clinicians, researchers, and practitioners across the psychedelic ecosystem, ensuring they are well-prepared to deliver safe, effective, and ethical care.
Evidence-Based Curriculum
Our courses are grounded in the latest scientific research and clinical best practices, providing a solid foundation for understanding the therapeutic potential and challenges of psychedelic-assisted treatments.
Accredited, Self-Paced Learning
With our online, self-paced learning platform, you can access course materials anytime, anywhere, allowing you to balance your education with your professional and personal commitments.
Foundational Knowledge
Our courses provide a strong foundation in psychedelic-assisted therapy, preparing you for future specializations and advanced training tailored to your specific interests and professional goals. Â
Psychedelic Training Modules
Our modular curriculum covers essential topics for the safe, effective, and ethical practice of psychedelic-assisted therapy, providing a structured learning path for healthcare professionals.
M1: Safety in Psychedelic-Assisted Therapy
A comprehensive overview of potential risks, side effects, contraindications, drug interactions, and strategies for ensuring patient safety before, during, and after PAT sessions.
M2: Patient Assessment & Selection
Guidelines for evaluating patients to determine suitability for PAT. This includes identifying red flags, understanding psychological risk factors, and developing a comprehensive patient screening process.
M3: Ethical Considerations
Exploration of unique ethical dilemmas in PAT, including informed consent, power dynamics, boundaries, and the potential for misuse or abuse.
M4: Legality of Psychedelic Therapies
A detailed breakdown of the current legal landscape governing the use of psychedelic substances in therapy. This covers regulatory frameworks, scheduling of controlled substances, and evolving legal guidelines across different jurisdictions.
M5: Science/Mechanisms of Action
Explore the hypothesized neurological and psychological mechanisms by which psychedelic substances facilitate therapeutic change. Discuss the potential interplay between neurochemistry, neuroplasticity, and the subjective experience during PAT.
M6: Therapeutic Models & Protocols
A brief overview of different therapy protocols used in psychedelic research and practice, including distinctions between models like PSIP (Psychedelic Somatic Interactional Psychotherapy) and other sitter models.
– November 30, 2016
1. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer
Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby and Brian L Schmidt.
– November 30, 2016
2. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer
Roland R Griffiths, Matthew W Johnson1, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano and Margaret A Klinedinst.
– September 6, 2010
3. Psilocybin treatment for anxiety in patients with advanced-stage cancer
Charles S Grob, Alicia L Danforth, Gurpreet S Chopra, Marycie Hagerty, Charles R McKay, Adam L Halberstadt, George R Greer.
– November 30, 2016
1. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer
Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone, Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby and Brian L Schmidt.
– November 30, 2016
2. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer
Roland R Griffiths, Matthew W Johnson1, Michael A Carducci, Annie Umbricht, William A Richards, Brian D Richards, Mary P Cosimano and Margaret A Klinedinst.
– September 6, 2010
3. Psilocybin treatment for anxiety in patients with advanced-stage cancer
Charles S Grob, Alicia L Danforth, Gurpreet S Chopra, Marycie Hagerty, Charles R McKay, Adam L Halberstadt, George R Greer.